Webinar: Using Patient Data to Better Understand Disease Progression in NASH
Nonalcoholic steatohepatitis (NASH), liver inflammation and damage caused by a buildup of fat in the liver, has historically been under-diagnosed. Untreated, the condition can lead to liver scarring and ultimately cirrhosis. 30 million adult Americans may have the misunderstood disease, with $5 billion currently being spent in annual related healthcare costs. Those costs will increase significantly by 2030 if NASH goes unchecked.
Unlike other liver diseases, NASH development pathways have not been well understood and FDA-approved treatments unavailable. In addition, many healthcare providers have been hesitant to test patients, particularly because a definitive diagnosis requires an invasive liver biopsy.
Recently, growing clinical acceptance of non-invasive biomarkers to measure fibrosis have opened up new pathways to understanding the progression of the disease. New therapies for NASH have now been developed, giving new hope to patients. Yet, for stakeholders like life sciences companies who are focused on fighting NASH, these breakthroughs create a new set of challenges: how to develop a better understanding of the disease’s epidemiology to guide treatment development and delivery.
New analytic approaches that focus on clinical encounter data allow organizations to see the “ground truth” for NASH patients and the healthcare providers who treat them. As life sciences companies shine brighter spotlights on rarer diseases, better data can lead to better clinical and financial outcomes.
This will be the subject of an upcoming webinar that I will host. In the webinar, we’ll explore how combining large clinical encounter data sets and composite blood test results has helped map the patient landscape for NASH as well as the impact of AI-facilitated insights.
Join us for the webinar on Monday, November 18 at 11:00 a.m. ET to learn more.